Generare Bioscience

Generare Bioscience is a biotechnology company focused on discovering novel drug leads and high-value molecules from microbial origins. Founded in Paris in 2023 by CEO Guillaume Vandenesch and CSO Dr. Vincent Libis, the company aims to revitalize the field of natural product discovery. Vandenesch is a biotech engineer with a background in accelerating deep-tech startups, while Dr. Libis is a researcher in synthetic biology, co-founder of Abolis Biotechnologies, and a former postdoctoral researcher at Rockefeller University. Their combined expertise underpins Generare's data-driven platform, which is the culmination of a decade of research in synthetic biology, DNA sequencing, and computational biology.

The company addresses a key bottleneck in pharmaceutical research: the decline in the discovery of new natural products, which have historically been a significant source of medicines, contributing to over 500 approved drugs. Generare's platform is designed to unlock the 97% of microbial chemical diversity that remains unexplored. It operates by sourcing microbial strains from the environment, primarily soil bacteria, and breaking down their genetic code to uncover untapped bioactive molecules. The core of its technology is a patent-pending shotgun cloning technique that fragments thousands of bacterial genomes into millions of pieces. This allows the company to express hundreds of gene clusters in parallel, exponentially increasing the speed and probability of identifying molecules with therapeutic potential, such as antibiotic or anticancer effects.

Generare's business model involves using its discovery engine to identify high-potential molecules and then patenting and licensing them to partners in the pharmaceutical, agricultural, and cosmetics industries. The company has already identified over 100 new molecules. In October 2024, Generare announced it had raised €5 million in a seed funding round from investors including Teampact.ventures, Galion.Exe, and VIVES Partners. This capital is intended to refine the technology, expand its genetic data library, and industrialize its discovery process into a scalable 'discovery factory'. The company has already formed a strategic partnership with French biotech Aurobac Therapeutics to accelerate drug discovery and development. Generare has received significant recognition, including the i-Lab Prize in 2024 and a prestigious ERC Starting Grant awarded to Dr. Libis for groundbreaking research.

Keywords: microbial drug discovery, natural product discovery, synthetic biology, shotgun cloning, bioactive molecules, microbial DNA, biosynthesis, computational biology, genome mining, drug lead discovery, anti-infectives, anticancer, immunosuppressants, agricultural biotech, cosmetics ingredients, Aurobac Therapeutics, Guillaume Vandenesch, Vincent Libis, Teampact.ventures, Galion.Exe, VIVES Partners, deeptech, life sciences, pharmaceutical licensing, genetic engineering, metagenomics